Predict your next investment

Corporation
vancpharm.com

See what CB Insights has to offer

Partners & Customers

1

About VANC Pharmaceuticals

VANC Pharmaceuticals (TSX VENTURE:NPH) (OTCQB:NUVPF) is a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets. The company develops, manufactures, and markets infection control products, and has developed a technology that is effective in killing several infectious organisms. VANC's major markets are hospitals, medical clinics, nursing homes, medical and dental offices, laboratories, emergency services, and food manufacturing plants in Canada and elsewhere.

VANC Pharmaceuticals Headquarter Location

170-4320 Viking Way

Richmond, British Columbia, V6V 2L4,

Canada

604-687-2038

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest VANC Pharmaceuticals News

VANC Pharmaceuticals Inc. Provides Corporate Update

Nov 1, 2018

| Source: VANC Pharmaceuticals VANCOUVER, British Columbia, Nov. 01, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) is excited to announce that further to its news release announced October 25, 2018, the Company has received TSX Venture Exchange approval to change its name (the “Name Change”) to Avricore Health Inc. “We are pleased to have received TSX approval for our new name, Avricore Health. This is an important, albeit symbolic step in our transformation of the company, its core services and product portfolio going forward,” said Mr. Bob Rai, CEO of VANC. The name Avricore Health is derived from the Greek word “avrio” meaning “tomorrow” and the English word “core”, signaling the company’s commitment to becoming a health innovator and applying the technologies of tomorrow to the core health issues of today, empowering pharmacists and pharmaceutical companies in Canada and in other countries with innovative products, services and information to optimize patient health. Effective at the open of the market on Monday, November 5th, 2018, VANC will be trading under its new name Avricore Health Inc. The new trading symbol will be AVCR. The CUSIP AND ISIN numbers have changed to 054521109 and CA0545211090 respectively. About VANC Pharmaceuticals Inc.  For more information, please contact Bob Rai at 604-247-2639 or by email at info@vancpharm.com . Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact: 604-247-2639

VANC Pharmaceuticals Acquisitions

1 Acquisition

VANC Pharmaceuticals acquired 1 company. Their latest acquisition was HealthTab on December 05, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/5/2016

Acquired

1

Date

12/5/2016

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired

Sources

1

VANC Pharmaceuticals Partners & Customers

1 Partners and customers

VANC Pharmaceuticals has 1 strategic partners and customers. VANC Pharmaceuticals recently partnered with bioLytical Laboratories on May 5, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

5/17/2017

Licensor

bioLytical Laboratories

United States

VANC Pharmaceuticals Announces Canadian Distribution Agreement for INSTI® HIV-1/HIV-2 Antibody Test.

VANCOUVER , BRITISH COLUMBIA -- -LRB- Marketwired - May 17 , 2017 -RRB- - VANC Pharmaceuticals Inc. -LRB- TSX VENTURE : VANC Pharmaceuticals Inc. -RRB- -LRB- : NUVPD -RRB- -LRB- `` VANC Pharmaceuticals Inc. '' or the `` Company '' -RRB- , a pharmaceutical company focused on the Canadian generic drug and over-the-counter -LRB- the `` OTC '' -RRB- markets , announces today it has entered into a Canada-wide distribution agreement for HIV-2 Antibody Test ® HIV-1 / HIV-2 Antibody Test .

5

Date

5/17/2017

Type

Licensor

Business Partner

bioLytical Laboratories

Country

United States

News Snippet

VANC Pharmaceuticals Announces Canadian Distribution Agreement for INSTI® HIV-1/HIV-2 Antibody Test.

VANCOUVER , BRITISH COLUMBIA -- -LRB- Marketwired - May 17 , 2017 -RRB- - VANC Pharmaceuticals Inc. -LRB- TSX VENTURE : VANC Pharmaceuticals Inc. -RRB- -LRB- : NUVPD -RRB- -LRB- `` VANC Pharmaceuticals Inc. '' or the `` Company '' -RRB- , a pharmaceutical company focused on the Canadian generic drug and over-the-counter -LRB- the `` OTC '' -RRB- markets , announces today it has entered into a Canada-wide distribution agreement for HIV-2 Antibody Test ® HIV-1 / HIV-2 Antibody Test .

Sources

5

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.